Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Patients With Indolent Lymphomas Exhibit Long-Term Survival With Tositumomab After Rituximab Failure: Presented at ASH By Ed Susman NEW ORLEANS -- December 9, 2009 -- Patients whose indolent lymphoma has progressed following treatment with rituximab may achieve long-term survival with follow-up therapy with a tositumomab and iodine I131 tositumomab therapeutic regimen, researchers stated here at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. “Median survival was 6.7 years after receiving tositumomab and iodine [I131] tositumomab,” said Sandra Horning, MD, Lymphoma Committee of the Eastern Cooperative Cancer Group, and Stanford University, Stanford, California, during her poster presentation on December 8. For the study, 40 patients with indolent, follicular large-cell, or transformed B-cell lymphoma that had progressed despite at least 1 course of treatment with rituximab were recruited from July 1998 to November 1999. Some of the patients had received 11 courses of various therapies before entering the trial with tositumomab and iodine I131 tositumomab. Dr. Horning said that over about 38% of these patients achieved a complete response rate, and 72% of the patients responded to therapy. The average duration of the response was 18.9 months. The mean progression-free survival for all 40 patients was about 10.4 months. “Of the patients who had a response to treatment, 39% of them were in continued response at 5 years, including 5 of the 9 complete responders,” said Dr. Horning. “These data demonstrate durable response rates of tositumomab and iodine I131 tositumomab in an indolent lymphoma population with disease progression after rituximab.” Mean age was 57 years and 13 of the patients were women. Twenty-six of the patients were diagnosed with follicular lymphoma and 10 patients were diagnosed with transformed B-cell lymphoma, the others were diagnosed with different forms of indolent disease. The patients included 24 who did not respond to rituximab therapy and 11 whose response lasted less than 6 months. They were treated with a therapeutic dose (0.65 to 0.75 Gy) of iodine I131 tositumomab based on total-body dosimetry. The median number of prior treatments was 4. To date, 20 deaths have been reported, 10 without documented disease progression. There were no cases of hypothyroidism reported as an adverse event. Funding for this study was provided by GlaxoSmithKline. [Presentation title: Tositumomab and Iodine I-131 Tositumomab (Bexxar Therapeutic Regimen) for Non-Hodgkin’s Lymphoma Patients Who Progressed After Treatment With Rituximab: Long Term Follow-Up of a Multi-Center Phase II Study. Abstract 2732] E-mail this page to a friend or colleague! To print, use this version